FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a nucleic acid molecule encoding a chimeric antigen receptor aimed at PSCA (prostate stem cell antigen), a human T-cell population for the treatment of cancer expressing PSCA, a composition containing a population of autologous or allogenic human T-cells for use in a method for the treatment of cancer expressing PSCA in a patient, and a chimeric antigen receptor aimed at PSCA. In one of embodiments, a nucleic acid molecule expresses polypeptide containing an amino acid sequence selected from SEQ ID NO: 26, 28, 30, 32, 34 and 36.
EFFECT: invention expands the arsenal of means encoding a chimeric antigen receptor aimed at PSCA.
14 cl, 23 dwg, 4 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| CENTRAL MEMORY T-CELLS FOR ADOPTIVE T-CELL THERAPY | 2015 |
|
RU2763523C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | 2013 |
|
RU2729401C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CELL | 2014 |
|
RU2717984C2 |
